Trial Summary
What is the purpose of this trial?
The main purpose of this study is to determine the threshold level of lower extremity CIPN symptoms that put patients who have been prescribed a neurotoxic chemotherapy agent (e.g., paclitaxel, docetaxel, oxaliplatin or cisplatin) as part of their treatment regimen for cancer at-risk for falling. The investigators believe that by specifying early CIPN symptoms that predict fall-risk, The investigators will ultimately be able to identify at-risk patients who could be referred to rehabilitative services to prevent injurious falls while enabling them to continue the chemotherapy treatment that could save their lives.
Research Team
Laura Gilchrist, PhD
Principal Investigator
Allina Health
Eligibility Criteria
This trial is for adults over 45 with a new cancer diagnosis, excluding primary brain tumors. Participants must be prescribed taxane or platinum-based chemotherapy and able to walk unassisted. They should speak English, manage their own transport, commit to thrice-weekly symptom tracking via an app on their smartphone for up to 9 months.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Mobile Ecological Momentary Assessment (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Allina Health System
Lead Sponsor